Kazia Therapeutics Ltd Sponsored ADR
Kazia Therapeutics Ltd Sponsored ADR is a clinical-stage biotechnology company focused on oncology drug development. The company’s current programs center on investigational cancer therapies, including paxalisib, a brain-penetrant small-molecule candidate being developed for hard-to-treat brain tumors, and EVT801, a selective inhibitor targeting pathways involved in tumor growth and angiogenesis. Kazia Therapeutics also advances other research-stage assets aimed at addressing unmet needs in cancer treatment. Its work spans pharmaceutical discovery, preclinical research, and clinical development, with a particular emphasis on brain cancer and other aggressive solid tumors. As an ADR structure, it provides U.S. market access to an Australian-based biotechnology company whose business is concentrated on experimental therapeutics rather than commercialized products.
$7.25
-$0.15 (-2.03%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-33850.00% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 98.2% YoY. Margins deteriorated 32616.8pp alongside, both lines moving the wrong way.
ROIC dropped from -192.68% to -2180.86%, capital efficiency is deteriorating. Negative free cash flow of -A$13M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
A$42K
▼ -98.2% YoY
Net Income (TTM)
-A$21M
▲ +22.7% YoY
Op. Margin
-33850.00%
▼ -32616.8pp YoY
ROIC
-2180.86%
▼ -1988.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-A$13M
▼ -38.6% YoY
Op. Cash Flow (TTM)
-A$13M
▼ -38.6% YoY
Net Debt
-A$4M
Net Cash Position
Cash & Equiv.
A$4M
Continue Research
Is Kazia Therapeutics Ltd Sponsored ADR (KZIA) overvalued?
Kazia Therapeutics Ltd Sponsored ADR (KZIA)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Kazia Therapeutics Ltd Sponsored ADR scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Kazia Therapeutics Ltd Sponsored ADR a high-quality business?+
Kazia Therapeutics Ltd Sponsored ADR scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -33,850.0% operating margin and a -2,180.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Kazia Therapeutics Ltd Sponsored ADR a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh KZIA's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.